NCT04224701 - A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

July 5, 2023

Study Completion Date

August 2, 2023

Conditions

HIV Infections

Interventions

BIOLOGICAL

BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted

30 µg

BIOLOGICAL

BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted

300 µg

BIOLOGICAL

Placebo

Tris NaCl Diluent

Trial Locations (3)

Rockefeller University, New York

George Washington University, Washington D.C.

The Amsterdam University Medical Centers, Amsterdam